|
Hypertensive disease
|
0.300 |
GeneticVariation
|
group |
BEFREE |
To this end, rats with hypertension induced by N<sup>G</sup>-nitro-L-arginine methylester (L-NAME) or high fructose drinking (HFD), and spontaneously hypertensive rats (SHRs) were used to explore the effects/mechanisms of NPY on BP using functional, molecular, and electrophysiological approaches.
|
31659606 |
2019 |
|
Hypertensive disease
|
0.300 |
Biomarker
|
group |
BEFREE |
Evidence suggests that interplay between bone marrow, microglia and immune mediators underlies the development of arterial hypertension, in particular through mechanisms involving cytokines and peptides, such as neuropeptide Y, substance P, angiotensin II and angiotensin-(1-7).
|
30894678 |
2019 |
|
Hypertensive disease
|
0.300 |
AlteredExpression
|
group |
BEFREE |
Abnormal regulation of NPY is involved in the development of a wide range of diseases, including obesity, hypertension, atherosclerosis, epilepsy, metabolic disorders, and many cancers.
|
29310113 |
2018 |
|
Hypertensive disease
|
0.300 |
Biomarker
|
group |
BEFREE |
Abnormal migration of vascular smooth muscle cells (VSMCs) serves an important role in hypertension, atherosclerosis and restenosis following angioplasty, which is regulated numerous hormonal and humoral factors, including neuropeptide Y (NPY) and dopamine.
|
28849020 |
2017 |
|
Hypertensive disease
|
0.300 |
Biomarker
|
group |
BEFREE |
NPY/Y₁ receptor-mediated vasoconstrictory and proliferative effects in pulmonary hypertension.
|
24779394 |
2014 |
|
Hypertensive disease
|
0.300 |
GeneticVariation
|
group |
BEFREE |
The aim of this study was to investigate the possible influence of NPY polymorphisms on hypertension in a South Indian population.
|
20033074 |
2010 |
|
Hypertensive disease
|
0.300 |
Biomarker
|
group |
RGD |
Nerve stimulation induced overflow of neuropeptide Y and modulation by angiotensin II in spontaneously hypertensive rats.
|
18835922 |
2008 |
|
Hypertensive disease
|
0.300 |
GeneticVariation
|
group |
BEFREE |
As the PreproNPY Leu7Pro polymorphism probably changes the intracellular processing of the synthesized preproNPY peptide, we assessed the hypothesis that PreproNPY Leu7Pro polymorphism is a risk factor for type II diabetes, impaired glucose tolerance and hypertension.
|
17268419 |
2007 |
|
Hypertensive disease
|
0.300 |
Biomarker
|
group |
LHGDN |
Neuropeptide Y and sympathetic control of vascular tone in hypertension.
|
16382999 |
2006 |
|
Hypertensive disease
|
0.300 |
Biomarker
|
group |
RGD |
Central administration of neuropeptide Y in nontransgenic rats also reduced (by 10.2+/-1.6 mm Hg) the NO deficiency hypertension, whereas a neuropeptide Y1 receptor antagonist centrally administered in the transgenic subjects during NO deficiency hypertension completely attenuated the depressor effect of neuropeptide Y upregulation.
|
15699473 |
2005 |
|
Hypertensive disease
|
0.300 |
Biomarker
|
group |
BEFREE |
Epistatic interaction between beta2-adrenergic receptor and neuropeptide Y genes influences LDL-cholesterol in hypertension.
|
15364898 |
2004 |
|
Hypertensive disease
|
0.300 |
Biomarker
|
group |
BEFREE |
This study provides important evidence suggesting that the Pro7 substitution in the prepro-NPY is an important risk factor for accelerated atherosclerotic progression, increased blood pressure and increased serum cholesterol in humans.
|
11689216 |
2001 |